Hypothesis

Emodin, a natural anthraquinone from rhubarb, functions not as a senolytic but as a senomorphic agent that reinstates circadian clock amplitude in senescent cells, thereby dampening the senescence‑associated secretory phenotype (SASP) through coordinated inhibition of EGFR/MAPK signaling and NF‑κB‑driven transcription.

Mechanistic Rationale

1. Emodin inhibits EGFR/MAPK – demonstrated in macrophage polarization and cancer cell sensitization [39078513], [PMC6756157]; this pathway converges on the core clock by phosphorylating CRY1 and PER2, leading to their degradation and reduced BMAL1:CLOCK transcriptional activity.
2. Clock‑NF‑κB coupling – CLOCK:BMAL1 directly represses NF‑κB p65 transactivation and drives expression of autophagy genes (e.g., LC3, BECN1) that limit SASP [40900376]; conversely, NF‑κB activation suppresses BMAL1 transcription, creating a vicious loop in senescence.
3. Emodin‑mediated EGFR/MAPK blockade stabilizes CRY1/PER2, enhancing BMAL1:CLOCK binding to E‑box promoters of clock‑controlled genes (CCGs) including Nrf2, Sirt1, and Atg5. Increased BMAL1:CLOCK activity consequently:
   • Reinforces circadian oscillations of DNA‑repair and homeostatic genes.
   • Boosts autophagic flux, clearing damaged mitochondria and limiting cGAS‑STING activation.
   • Directly antagonizes NF‑κB nuclear translocation, reducing transcription of SASP components (IL‑6, IL‑8, MCP‑1, PAI‑1).
4. Senomorphic outcome – Senescent cells retain viability but exhibit a shifted secretome toward a low‑inflammatory, tissue‑supportive profile, aligning with the concept that p16^INK4a^ and p21^CIP1^ subpopulations can be differentially modulated without cell elimination [PMC10723333] .

Testable Predictions

• In vitro: Induced senescence (e.g., IR or oncogenic RAS) in human fibroblasts will show:
  • Increased PER2::LUC bioluminescence amplitude after 24 h emodin treatment (5–20 µM) relative to DMSO.
  • Elevated BMAL1 occupancy at E‑box promoters (ChIP‑qPCR) and decreased p‑ERK1/2 levels.
  • Reduced SASP cytokine secretion (ELISA) without significant changes in SA‑β‑gal positivity or cell count.
  • Rescue of autophagic flux (LC3‑II/I ratio, p62 degradation) and diminished NF‑κB p65 nuclear immunoreactivity.
• In vivo: Aging (24‑month) C57BL/6 mice receiving emodin (30 mg/kg, i.p., thrice weekly) for 8 weeks will display:
  • Restored circadian rhythmicity in wheel‑running activity and peripheral clock gene expression (qPCR of liver, hippocampus).
  • Lower plasma SASP factors (IL‑6, TNF‑α) and reduced NF‑κB p65 phosphorylation in tissue lysates.
  • Improved functional endpoints (grip strength, treadmill endurance) without detectable senescent cell clearance (p16^Ink4a^‑GFP reporter unchanged).

Falsifiability

If emodin fails to enhance BMAL1:CLOCK transcriptional activity or rhythm amplitude in senescent cells, or if SASP suppression occurs independently of circadian readouts (e.g., persists in BMAL1‑knockout contexts), the hypothesis would be refuted. Conversely, a robust correlation between clock restoration and SASP attenuation across multiple cell types and species would support the proposed senomorphic mechanism.

Broader Implications

Positioning the circadian clock as a regulatory "firewall" suggests that compounds like emodin can re‑synchronize aging‑disrupted temporal programs, offering a unified strategy to temper SASP heterogeneity without the risks associated with senolytic clearance. This approach may be especially valuable in contexts where senescent cells contribute beneficially (e.g., wound healing) or where complete elimination is undesirable.